Cargando…
Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A
Therapeutic agents are urgently needed for treating metastatic castration‐refractory prostate cancer (mCRPC) that is unresponsive to androgen deprivation and chemotherapy. Our screening assays demonstrated that chemotherapy‐resistant prostate cancer (PCa) cells are more sensitive to HDAC inhibitors...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824406/ https://www.ncbi.nlm.nih.gov/pubmed/29327812 http://dx.doi.org/10.1111/jcmm.13475 |
_version_ | 1783302018824142848 |
---|---|
author | Xu, Qingqing Liu, Xiaofei Zhu, Shiqin Hu, Xuelei Niu, Huanmin Zhang, Xiulei Zhu, Deyu Nesa, Effat Un Tian, Keli Yuan, Huiqing |
author_facet | Xu, Qingqing Liu, Xiaofei Zhu, Shiqin Hu, Xuelei Niu, Huanmin Zhang, Xiulei Zhu, Deyu Nesa, Effat Un Tian, Keli Yuan, Huiqing |
author_sort | Xu, Qingqing |
collection | PubMed |
description | Therapeutic agents are urgently needed for treating metastatic castration‐refractory prostate cancer (mCRPC) that is unresponsive to androgen deprivation and chemotherapy. Our screening assays demonstrated that chemotherapy‐resistant prostate cancer (PCa) cells are more sensitive to HDAC inhibitors than paired sensitive PCa cells, as demonstrated by cell proliferation and apoptosis in vitro and in vivo. Kinetic study revealed that TSA‐induced apoptosis was significantly dependent on enhanced transcription and protein synthesis in an early stage, which subsequently caused ER stress and apoptosis. ChIP analysis indicated that TSA increased H4K16 acetylation, promoting ER stress gene transcription. The changes in Ac‐H4K16, ATF3 and ATF4 were also validated in TSA‐treated animals. Further study revealed the higher enzyme activity of HDACs and an increase in acetylated proteins in resistant cells. The higher nucleocytoplasmic acetyl‐CoA in resistant cells was responsible for elevated acetylation status of protein and a more vigorous growth state. These results strongly support the pre‐clinical application of HDAC inhibitors for treating chemotherapy‐resistant mCRPC. |
format | Online Article Text |
id | pubmed-5824406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58244062018-03-01 Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A Xu, Qingqing Liu, Xiaofei Zhu, Shiqin Hu, Xuelei Niu, Huanmin Zhang, Xiulei Zhu, Deyu Nesa, Effat Un Tian, Keli Yuan, Huiqing J Cell Mol Med Original Articles Therapeutic agents are urgently needed for treating metastatic castration‐refractory prostate cancer (mCRPC) that is unresponsive to androgen deprivation and chemotherapy. Our screening assays demonstrated that chemotherapy‐resistant prostate cancer (PCa) cells are more sensitive to HDAC inhibitors than paired sensitive PCa cells, as demonstrated by cell proliferation and apoptosis in vitro and in vivo. Kinetic study revealed that TSA‐induced apoptosis was significantly dependent on enhanced transcription and protein synthesis in an early stage, which subsequently caused ER stress and apoptosis. ChIP analysis indicated that TSA increased H4K16 acetylation, promoting ER stress gene transcription. The changes in Ac‐H4K16, ATF3 and ATF4 were also validated in TSA‐treated animals. Further study revealed the higher enzyme activity of HDACs and an increase in acetylated proteins in resistant cells. The higher nucleocytoplasmic acetyl‐CoA in resistant cells was responsible for elevated acetylation status of protein and a more vigorous growth state. These results strongly support the pre‐clinical application of HDAC inhibitors for treating chemotherapy‐resistant mCRPC. John Wiley and Sons Inc. 2018-01-12 2018-03 /pmc/articles/PMC5824406/ /pubmed/29327812 http://dx.doi.org/10.1111/jcmm.13475 Text en © 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Xu, Qingqing Liu, Xiaofei Zhu, Shiqin Hu, Xuelei Niu, Huanmin Zhang, Xiulei Zhu, Deyu Nesa, Effat Un Tian, Keli Yuan, Huiqing Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A |
title | Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A |
title_full | Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A |
title_fullStr | Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A |
title_full_unstemmed | Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A |
title_short | Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A |
title_sort | hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor trichostatin a |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824406/ https://www.ncbi.nlm.nih.gov/pubmed/29327812 http://dx.doi.org/10.1111/jcmm.13475 |
work_keys_str_mv | AT xuqingqing hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina AT liuxiaofei hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina AT zhushiqin hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina AT huxuelei hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina AT niuhuanmin hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina AT zhangxiulei hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina AT zhudeyu hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina AT nesaeffatun hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina AT tiankeli hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina AT yuanhuiqing hyperacetylationcontributestothesensitivityofchemoresistantprostatecancercellstohistonedeacetylaseinhibitortrichostatina |